Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ACSL1 | P33121 | 11/20 | 0.51 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.50 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26637455 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3ACSL1ACSL3 | |
| SCHEMBL29711702 | 0.85 | SLC6A4 (0.67) | SLC6A2SLC6A4SLC6A3LNPEP | |
| SCHEMBL1416985 | 0.85 | SLC6A4 (0.67) | SLC6A2SLC6A4SLC6A3LNPEP | |
| SCHEMBL30663064 | 0.84 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3ACSL1LNPEP | |
| SCHEMBL1749499 | 0.82 | ACSL1 (0.56) | SLC6A2SLC6A4SLC6A3ACSL1ACSL3 | |
| SCHEMBL664031 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3ACSL1ACSL3 | |
| SCHEMBL10147937 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3ACSL1ACSL3 | |
| SCHEMBL25184897 | 0.81 | POLB (0.51) | ACSL1ACSL3ACSL6EPHX2 | |
| SCHEMBL25184896 | 0.81 | POLB (0.51) | ACSL1ACSL3ACSL6EPHX2 | |
| SCHEMBL15637209 | 0.79 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | SLC6A2 2797/4885SLC6A4 3815/4885SLC6A3 2601/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | SLC6A2 2797/4885SLC6A4 3815/4885SLC6A3 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.